Salutar, Inc.

Sonus Pharmaceuticals, Inc.

Nastech Pharmaceutical Company, Inc.

Atossa Therapeutics, Inc.

Par Pharmaceutical, Inc.

Marina Biotech, Inc.

Atossa Healthcare, Inc.

Amersham Health As

K-quay Enterprises, LLC

Other

Retrophin, Inc.

Qol Medical LLC

Mdrna, Inc.

Atossa Genetics, Inc.

Amylin Pharmaceuticals, Inc.

Steven C Quay

Scott M Rocklage

Anthony P Sileno

Michael E Houston, Jr

Panayiotis P Constantinides

Henry R Costantino

John Michael Newsam

Edward Thomas Kisak

Zenaida Go

LungHu Wang

Yao-Lin Sun

ChangJung Wu

ChuanDer Huang

Karel J Lambert

Peter C Aprile

Mary Gallagher Prieve

Pierrot Harvie

Roger C Adami

Kathy L Fosnaugh

Shaguna Seth

Mary S Kleppe

Renata Fam

Gordon Brandt

Alexander K Tustian

Conor J MacEvilly

Debra L Quay

Warren K Miller

Dilip M Worah

Jorge C De Meireles

Arati Deshpande

Paul Hickok Johnson

Alan D Watson

Richard E Herman

Douglas L Badders

Paul F Sieving

Zenaida O Go

Ching-Yuan Li

Karl F Kraft

Dean R Kessler

Antony P Sileno

James Mcswiggen

Narendra Vaish

Nagesh Palepu

Naresh Kumar Reddy Vutukuru

Srinivasan Shanmugam

Joshua Sestak

Mohammad Ahmadian

Shu-Chih Chen

Michael Houston

Alexis Kays Leonard

Lalit Raj Peddakota

Ronald A Roy

Kayvon Emile Sharghi

Dilip Worah

Garland M Bellamy

Jason Philip Gesty

Annemarie Stoudt Cohen

Avadhesh S Kushwaha

Shu-Chih Chen Quay

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

Methods for making and using endoxifen

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

The present disclosure provides sustained release compositions of (Z)-endoxifen and polymorphs and salts thereof and methods of making sustained release compositions of (Z)-endoxifen and polymorphs and salts thereof. The present disclosure also provides methods for treating disorders susceptible to (Z)-endoxifen, including hormone dependent disorders and mood disorders.

Sustained release compositions of endoxifen

This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Tyrosine-based lipids for delivery of therapeutics

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum&#xd7;100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Arginine-based lipids for delivery of therapeutics

An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of &#x3b1;-tocotrienol, &#x3b2;-tocotrienol, &#x3b3;-tocotrienol, or &#x3b4;-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg &#x3b4;-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.

Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof

The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.

Nicked or gapped nucleic acid molecules and uses thereof

Biological samples of mammary fluid or components thereof are obtained using a breast pump device coupled with an absorbent paper or membrane, optionally facilitated by administering oxytocin to the subject. The breast pump device stimulates expression of mammary fluid and provides for collection of diagnostic samples on the absorbent paper or membrane to evaluate breast disease, including cancer. The biological sample may include fluid containing one or more of cells or cellular components, proteins, glycoproteins, peptides, nucleotides or other desired constituents comprising a breast disease marker. Absorbent paper or membrane, and methods relating to the paper or membrane, and a breast pump device are also provided.

Absorbent paper and use thereof for breast cancer detection

Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

Intranasal carbetocin formulations and methods for the treatment of autism

Growing community of inventors

Edmonds, WA, United States of America

Steven C Quay